Western Blot: RelB Antibody [NBP2-20123] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with RelB antibody diluted at 1:1000. The HRP-conjugated anti-rabbit IgG ...read more
Immunohistochemistry-Paraffin: RelB Antibody [NBP2-20123] - Human breast carcinoma. RelB stained by RelB antibody diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.
Chromatin Immunoprecipitation: RelB Antibody [NBP2-20123] - Cross-linked ChIP was performed with THP-1 chromatin extract treated with LPS (1.0 ug/ml for 3 h) and 5 ug of either normal rabbit IgG or anti-RelB antibody. ...read more
Western Blot: Rel B Antibody [NBP2-20123] - Sample (30 ug of whole cell lysate) A: NIH-3T3 7. 5% SDS PAGE gel, diluted at 1:10000.
Western Blot: RelB Antibody [NBP2-20123] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with RelB antibody diluted at 1:5000. The ...read more
Immunoprecipitation: RelB Antibody [NBP2-20123] - HeLa whole cell lysate/extract A. Control with 2 ug of preimmune rabbit IgG B. Immunoprecipitation of RelB protein by 2 ug of RelB antibody 7.5% SDS-PAGE The ...read more
62 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read Publication using NBP2-20123 in the following applications:
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
PBS (pH 7), 20% Glycerol
0.025% Proclin 300
Immunogen affinity purified
Alternate Names for RelB Antibody
nuclear factor of kappalight polypeptide gene enhancer in B-cells 3
v-rel reticuloendotheliosis viral oncogene homolog B
NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our RelB Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.